School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

Amgen Inc AMGN

Healthcare · Biotechnology

$414.87last close 2026-10-09 · market cap $224.29B · delayed data

Trailing returns

1M+6.03%
3M+14.76%
6M+18.24%
1Y+44.32%
5Y+131.97%

Basis: Adjusted daily closes.

What it does

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis…

Open AMGN in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies